Anti-CD22-DIBO-doxorubicin ADC

  • Check with publisher
  • Published date: November 13, 2017
    • Shirley, New York, United States

This ADC product is comprised of an anti-CD22 monoclonal antibody conjugated via a DIBO linker to a doxorubicin. The doxorubicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, doxorubicin binds to DNA, causes DNA damage.
Doxorubicin is the generic name for the trade name drug, Adriamycin®, as well as, Rubex®, which is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.

Result 0 votes
Bella
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Anti-CD22 (Inotuzumab)-hydrazone-Calicheamicin ADC

    Anti-CD22 (Inotuzumab)-hydrazone-Calicheamicin ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of a Inotuzumab conjugated via a hydrazone linker to a Calicheamicin. The Calicheamicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the ce...

  • Anti-CD22 (Pinatuzumab)-Mc-VC-PABC-MMAE ADC

    Anti-CD22 (Pinatuzumab)-Mc-VC-PABC-MMAE ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of a Pinatuzumab conjugated via a Mc-VC-PABC linker to a MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds t...

  • Anti-CD22 (Epratuzumab)-MCC-DM1 ADC

    Anti-CD22 (Epratuzumab)-MCC-DM1 ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of a Epratuzumab conjugated via a MCC linker to a DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins...